One Year of Hepatitis B Immunoglobulin Plus Tenofovir Therapy is Safe and Effective in Preventing Recurrent Hepatitis B Infection Post-Liver Transplantation

Tomohiro Tanaka; Eberhard L Renner; Nazia Selzner; George Therapondos; Leslie B Lilly

doi:10.1155/2014/839014

Back

One Year of Hepatitis B Immunoglobulin Plus Tenofovir Therapy is Safe and Effective in Preventing Recurrent Hepatitis B Infection Post-Liver Transplantation

Journal article

Open access

Peer reviewed

One Year of Hepatitis B Immunoglobulin Plus Tenofovir Therapy is Safe and Effective in Preventing Recurrent Hepatitis B Infection Post-Liver Transplantation

Tomohiro Tanaka, Eberhard L Renner, Nazia Selzner, George Therapondos and Leslie B Lilly

Canadian journal of gastroenterology & hepatology, Vol.28(1), pp.41-44

2014

DOI: 10.1155/2014/839014

PMCID: PMC4071906

PMID: 24212911

Files and links (1)

url

https://doi.org/10.1155/2014/839014View

Published (Version of record) Open Access

Abstract

BACKGROUND: Hepatitis B immunoglobulin (HBIG) given in combination with a nucleos(t)ide analogue has reduced the rate of recurrent hepatitis B virus (HBV) infection following liver transplantation (LT); however, the most effective protocol remains unclear.OBJECTIVE: To evaluate the use of tenofovir disoproxil fumarate (TDF) in combination with one year of low-dose HBIG.METHODS: Twenty-four adults who underwent LT for HBV-related liver disease at the University Health Network (Toronto, Ontario) and received TDF (± lamivudine) and one year of HBIG to prevent recurrent HBV infection from June 2005 to June 2011 were evaluated.RESULTS: The median length of follow-up post-LT was 29.1 months. Three patients died during the follow-up period. Patient survival was 100% and 84.1% at one and five years, respectively. None of the patients developed recurrent HBV infection. No significant adverse event was observed due to TDF administration; renal function pre- and post-LT were also acceptably preserved.CONCLUSION: The present study demonstrated that a short, finite course of low-dose HBIG combined with maintenance of long-term TDF staring before LT is cost-effective and safe. However, further prospective study involving a larger patient cohort with a longer followup period is required to confirm the results.

Details

Title: Subtitle: One Year of Hepatitis B Immunoglobulin Plus Tenofovir Therapy is Safe and Effective in Preventing Recurrent Hepatitis B Infection Post-Liver Transplantation
Creators: Tomohiro Tanaka - Multi-Organ Transplant Program, Liver Transplant Unit, University Health Network, University of Toronto, Toronto, Ontario, Canada, Organ Transplantation Service, The University of Tokyo Hospital, Tokyo, Japan
Eberhard L Renner - Multi-Organ Transplant Program, Liver Transplant Unit, University Health Network, University of Toronto, Toronto, Ontario, Canada
Nazia Selzner - Multi-Organ Transplant Program, Liver Transplant Unit, University Health Network, University of Toronto, Toronto, Ontario, Canada
George Therapondos - Multi-Organ Transplant Program, Liver Transplant Unit, University Health Network, University of Toronto, Toronto, Ontario, Canada
Leslie B Lilly - Multi-Organ Transplant Program, Liver Transplant Unit, University Health Network, University of Toronto, Toronto, Ontario, Canada
Resource Type: Journal article
Publication Details: Canadian journal of gastroenterology & hepatology, Vol.28(1), pp.41-44
DOI: 10.1155/2014/839014
PMID: 24212911
PMCID: PMC4071906
NLM abbreviation: Can J Gastroenterol Hepatol
ISSN: 2291-2789
eISSN: 2291-2797
Language: English
Date published: 2014
Academic Unit: Gastroenterology and Hepatology; Internal Medicine
Record Identifier: 9984094739702771

Metrics

12 Record Views

22 Times Cited - Web of Science